Akebia Therapeutics (AKBA +3.7%) is up on below-average volume in response to the filing of a marketing application in Japan by collaboration partner Mitsubishi Tanabe Pharma seeking approval of vadadustat for the treatment of chronic kidney disease-associated anemia.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.